\
&
Contact us
Published on | 2 years ago
ProgrammesLetter of Intent for the Joint Call with Korea HORIZON-JU-Chips-2024-3-RIA
The applicants must submit a letter of intent in the relevant placeholder under ‘Letter of intent’ from the EU and Korean consortium (pdf only).
The letter of intent (template provided under the Calls documents) should include the intention to enter a ‘joint research partnership’ for common research goals of the EU-Korean joint consortium.
Please be informed that the Guideline for the letter of intent has been updated - please check the Calls documents section.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Culture and society EIT New European Bauhaus
EIT Culture & Creativity has opened its first funding calls as an implementing partner of the New European Bauhaus (NEB) Academy, the learning and innovation infrastructure of the NEB. These two calls offer a total of €6 million to support circular fashion and skills development for the transformation of Europe’s lived environme... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.